Lijuan Zhang

Lijuan Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2024 in Heliyon
Verified
Journal Article
Open access
YMYiZheng Ma
YiZheng Ma
JHJingBo Han
JingBo Han
KWKangFeng Wang
KangFeng Wang
HHHuan Han
Huan Han
YHYiBin Hu
YiBin Hu
LZLijuan Zhang
Lijuan Zhang
Atherosclerosis (AS) is a chronic inflammatory disease resulting from dysregulated lipid metabolism, constituting the pathophysiological foundation of cardiovascular and cerebrovascular diseases. AS has a high incidence rate and mortality rate worldwide. As such, traditional Chinese medicine (TCM) has been widely used recently due to its stable therapeutic effect and high safety. Ganoderma lucidum polysaccharides (GLP) are the main active ingredients of Ganoderma lucidum, a Chinese herbal medicine. Research has also shown that GLP has anti-inflammatory and antioxidant properties, regulates gut microbiota, improves blood glucose and lipid levels, and inhibits obesity. Most of the current research on GLP anti-AS is focused on animal models. Thus, its clinical application remains to be discovered. In this review, we combine relevant research results and start with the pathogenesis and risk factors of GLP on AS, proving that GLP can prevent and treat AS, providing a scientific basis and reference for the future prevention and treatment of AS with GLP.

13 January 2025 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
XGXiuju Guan
Xiuju Guan
HLHaitao Li
Haitao Li
LZLijuan Zhang
Lijuan Zhang
HZHongwei Zhi
Hongwei Zhi